Issue 155 • June 2025

Are regulators keeping pace with AI adoption in clinical trials?

AI is now used throughout clinical trials, from recruitment to analysis – but are regulators keeping up?

Briefing

Novo Nordisk’s CEO to step down as weight loss market share plummets

Feature

Power of collaboration more pertinent than ever says pharma experts

Feature

Newborn screening strategy needs modernising as HHS disbands advisory committee

Analyst Comment

Real-world data supports Trikafta as gold standard in long-term CF care

Go to article: Home | Are regulators keeping pace with AI adoption in clinical trials?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Cartherics Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: NiproGo to article: In DepthGo to article: Are regulators keeping pace with AI adoption in clinical trials?Go to article: Power of collaboration more pertinent than ever says pharma expertsGo to article: Newborn screening strategy needs modernising as HHS disbands advisory committeeGo to article: Pharma’s AI prospects get nudged into the future with EU’s AI actGo to article: ATS 2025: Anti–IL-5 therapy cuts exacerbations in coexisting COPD and asthma patientsGo to article: ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF careGo to article: B Medical Systems Company InsightGo to article: Endress+HauserGo to article: SCHOTT Pharma Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Buyer's GuidesGo to article: Next issue